Low PCDH7 immunoexpression has been associated with high pathological grade, recurrence, and tumor progression; this fact is an independent prognostic factor for clinical outcome (Lin et al., 2016) and is associated with BC invasiveness (Ma et al., 2013). Here, PCDH7 is linked to breast cancer.